Market Research Logo

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

Introduction
Global Markets Direct Report Coverage
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
ChironWells GmbH
RaQualia Pharma Inc
Vitality Biopharma Inc
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles
ORP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H1 2017
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H1 2017
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H1 2017
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H1 2017
List of Figures
Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

Summary

>Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;